METiS Therapeutics Teams Up with Eli Lilly on AI Delivery Tech, With Over $10 Million Upfront and Up to $1.1 Billion in Milestones

Metis TechBio has signed a delivery deal with Eli Lilly worth up to $1.1 billion. The agreement highlights the growing focus on AI in the pharmaceutical sector to reduce costs and development timelines. Metis TechBio's stock has seen a 5-day change of +6.62% and a year-to-date change of -10.04%.

Eli Lilly (LLY) plans to seek expanded approval for Omvoh in pediatric ulcerative colitis after positive Phase 3 trial results. 50% of clinical responders aged 6-17 achieved remission at Week 52. Omvoh is currently approved for adults with ulcerative colitis and Crohn's disease. The expansion could broaden the drug's market without requiring a new medication. Safety data was consistent with the adult profile. Investors will watch for regulatory filings and approval decisions.

Eli Lilly plans to seek pediatric approval for Omvoh after a Phase 3 trial showed 50% of 6-17 year-olds with ulcerative colitis achieved remission at 52 weeks. The drug is currently approved for adults. Expansion could broaden patient pool and boost revenues.

Eli Lilly reported positive one-year Phase 3 SHINE-2 study results for Omvoh in pediatric ulcerative colitis, with 50% of responders achieving clinical remission at Week 52. The study met its primary endpoint. Omvoh is approved for adults but not yet for pediatric use. The safety profile was consistent with adult data, with no new safety signals. Lilly is studying mirikizumab in pediatric inflammatory bowel disease.

Eli Lilly reported that 50% of pediatric patients (ages 6-17) who responded to Omvoh (mirikizumab-mrkz) at Week 12 achieved clinical remission at Week 52 in a Phase 3 trial. The company plans to submit these results for regulatory approval. Omvoh is currently approved for adults with ulcerative colitis. The trial had no placebo control group, and Lilly compared results to adult placebo data from a separate study.

Eli Lilly (LLY:NYSE) has partnered with Metis TechBio (7666.HK:HKSE) for up to $1.1B in a research deal on lipid nanoparticles, with most payments contingent on milestones. The upfront payment is in the low double-digit millions. Lilly's R&D spend was $14.6B over the last 12 months.